Emerging Biomarkers in Stage III Melanoma May Improve Patient Management

Source: Cancer Therapy Advisor, May 2021

Increased effort is needed in the development of reliable predictive biomarkers for stage III melanoma, according to a review published in the International Journal of Molecular Sciences.1

Gene expression analysis and the identification of a single gene or a signature correlated with patients’ outcomes could lead to improved patient stratification.

READ THE ORIGINAL FULL ARTICLE
Menu